Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 23 | -0.55 Increased by +25.68% | -0.67 Increased by +26.73% |
| Mar 17, 23 | -0.49 Increased by +47.31% | -0.80 Increased by +48.44% |
| Nov 4, 22 | -0.92 Decreased by -31.43% | -0.74 Decreased by -32.87% |
| Aug 4, 22 | -0.77 Increased by +7.23% | -0.86 Increased by +12.17% |
| May 6, 22 | -0.74 Decreased by -72.09% | -0.80 Increased by +9.38% |
| Feb 25, 22 | -0.93 Decreased by -8.14% | -0.82 Decreased by -16.36% |
| Nov 12, 21 | -0.70 Decreased by -11.11% | -0.91 Increased by +25.36% |
| Aug 13, 21 | -0.83 Decreased by -45.61% | -0.72 Decreased by -21.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -23.37 M Increased by +10.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -20.48 M Increased by +36.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -34.99 M Decreased by -43.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -27.21 M Increased by +5.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -26.01 M Decreased by -72.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -32.42 M Decreased by -9.13% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -24.33 M Decreased by -13.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -28.93 M Decreased by -78.52% | Decreased by N/A% Decreased by N/A% |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.